These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 35285577

  • 1. Unraveling Hürthle cell lesions of the thyroid using molecular findings.
    Wong KS.
    Cancer Cytopathol; 2022 Jun; 130(6):405-406. PubMed ID: 35285577
    [No Abstract] [Full Text] [Related]

  • 2. Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.
    Wong KS, Jo VY, Lowe AC, Faquin WC, Renshaw AA, Shah AA, Roh MH, Stelow EB, Krane JF.
    Cancer Cytopathol; 2020 Jan; 128(1):68-75. PubMed ID: 31751003
    [Abstract] [Full Text] [Related]

  • 3. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW.
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [Abstract] [Full Text] [Related]

  • 4. Hurthle cells in fine needle aspiration cytology of the thyroid: a potential diagnostic dilemma?
    Wong YP, Md Isa N, Md Zin RR, Noor Akmal S.
    Malays J Pathol; 2015 Apr; 37(1):49-52. PubMed ID: 25890614
    [Abstract] [Full Text] [Related]

  • 5. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma.
    Sponziello M, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, Durante C, Filetti S, Fadda G.
    Endocrine; 2018 Nov; 62(2):492-495. PubMed ID: 29700698
    [No Abstract] [Full Text] [Related]

  • 6. Letter to the Editor: Use of Molecular Diagnostic Tests in Thyroid Nodules with Hürthle Cell-Dominant Cytology.
    Endo M, Nabhan F, Angell TE, Harrell RM, Nasr C, Wei S, Sipos JA.
    Thyroid; 2020 Sep; 30(9):1390-1392. PubMed ID: 32228149
    [No Abstract] [Full Text] [Related]

  • 7. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
    Agarwal S, Bychkov A, Jung CK, Hirokawa M, Lai CR, Hong S, Kwon HJ, Rangdaeng S, Liu Z, Su P, Kakudo K, Jain D.
    Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
    [Abstract] [Full Text] [Related]

  • 8. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
    Elliott DD, Pitman MB, Bloom L, Faquin WC.
    Cancer; 2006 Apr 25; 108(2):102-9. PubMed ID: 16453320
    [Abstract] [Full Text] [Related]

  • 9. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
    Doerfler WR, Nikitski AV, Morariu EM, Ohori NP, Chiosea SI, Landau MS, Nikiforova MN, Nikiforov YE, Yip L, Manroa P.
    Endocr Relat Cancer; 2021 Apr 27; 28(5):301-309. PubMed ID: 33792557
    [Abstract] [Full Text] [Related]

  • 10. Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease.
    Alaedeen DI, Khiyami A, McHenry CR.
    Surgery; 2005 Oct 27; 138(4):650-6; discussion 656-7. PubMed ID: 16269293
    [Abstract] [Full Text] [Related]

  • 11. A case series of thyroid fine needle aspiration biopsies diagnosed as follicular neoplasm with oncocytic features.
    Chen CV, Krishnan V, Greenland NY.
    Diagn Cytopathol; 2024 Oct 27; 52(10):553-557. PubMed ID: 38581413
    [Abstract] [Full Text] [Related]

  • 12. Predictors of malignancy in patients with a thyroid nodule that contains Hürthle cells.
    Turanli S, Pirhan Y, Ozcelik CK, Cetin A.
    Otolaryngol Head Neck Surg; 2011 Apr 27; 144(4):514-7. PubMed ID: 21493226
    [Abstract] [Full Text] [Related]

  • 13. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
    Ren Y, Kyriazidis N, Faquin WC, Soylu S, Kamani D, Saade R, Torchia N, Lubitz C, Davies L, Stathatos N, Stephen AE, Randolph GW.
    Thyroid; 2020 Mar 27; 30(3):425-431. PubMed ID: 32013786
    [Abstract] [Full Text] [Related]

  • 14. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
    Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, Faquin WC, Parangi S.
    Thyroid; 2015 Jul 27; 25(7):789-96. PubMed ID: 25962906
    [Abstract] [Full Text] [Related]

  • 15. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
    Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P.
    Diagn Cytopathol; 2019 Oct 27; 47(10):977-985. PubMed ID: 31293091
    [Abstract] [Full Text] [Related]

  • 16. Thyroid nodules 2006: managing what has been known for over 50 years.
    Garber JR.
    Hormones (Athens); 2006 Oct 27; 5(3):179-86. PubMed ID: 16950751
    [No Abstract] [Full Text] [Related]

  • 17. Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.
    McFadden DG, Sadow PM.
    Front Endocrinol (Lausanne); 2021 Oct 27; 12():696386. PubMed ID: 34177816
    [Abstract] [Full Text] [Related]

  • 18. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms.
    Kim TH, Rodriguez EF, Lim D, Moatamed NA.
    Diagn Cytopathol; 2023 Nov 27; 51(11):705-711. PubMed ID: 37533334
    [Abstract] [Full Text] [Related]

  • 19. Challenges in Cytology Specimens With Hürthle Cells.
    Thodou E, Canberk S, Schmitt F.
    Front Endocrinol (Lausanne); 2021 Nov 27; 12():701877. PubMed ID: 34248855
    [Abstract] [Full Text] [Related]

  • 20. IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?
    Lupo M, Guttler R, Geck Z, Tonozzi TR, Kammesheidt A, Braunstein GD.
    Endocr Pract; 2018 May 27; 24(5):453-459. PubMed ID: 29498908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.